Macular Choroidal Volume Changes After Intravitreal Bevacizumab for Exudative Age-Related Macular Degeneration

Palkovits, Stefan; Seidel, Gerald; Pertl, Laura; Malle, Eva Maria; Hausberger, Silke; Makk, Johanna; Singer, Christoph; Osterholt, Julia; Herzog, Sereina A.; Haas, Anton; Weger, Martin

doi:10.1097/iae.0000000000001480

Cited by 3 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We hypothesized that the anti-VEGF treatment may influence retinal and choroidal exudation, reducing vascular hyperpermeability and resulting in a significant reduction of CMT and SFCT. Similar findings have been reported in earlier studies [23][24][25][26].…”

Section: Discussionsupporting

confidence: 92%

Prospective Study of Vessel Density by Optical Coherence Tomography Angiography After Intravitreal Bevacizumab in Exudative Age-Related Macular Degeneration

et al. 2019

View full text Add to dashboard Cite

Introduction: The aim of this study was to evaluate retinal and choriocapillaris (CC) vessel density, using optical coherence tomography angiography (OCTA), in the macular region at baseline and after three once-monthly intravitreal injections of bevacizumab (loading phase) in patients affected by exudative age-related macular degeneration (AMD). Methods: A total 38 eyes of 38 patients with exudative AMD (16 women, 22 men; mean age 72.47 ± 7.46 years) were included in this study. We evaluated vessel density in different macular areas (whole image, fovea and parafovea) of the superficial capillary plexus (SCP), deep capillary plexus (DCP) and CC. In addition, central macular thickness (CMT) and choroidal thickness in the foveal region and 500 lm in the Enhanced Digital Features To view enhanced digital features for this article go to https://doi.org/10.6084/ m9.figshare.9825536.

show abstract

Section: Discussionsupporting

confidence: 92%

Prospective Study of Vessel Density by Optical Coherence Tomography Angiography After Intravitreal Bevacizumab in Exudative Age-Related Macular Degeneration

et al. 2019

View full text Add to dashboard Cite

show abstract

“…It has been shown that choroid plays an important role in scleral remodeling via the synthesis of several growth factors including VEGF [35], hepatocyte growth factor [36], and basic fibroblast growth factor [37]. Previous studies revealed that IVB and IVR decrease choroidal thickness and volume significantly in an adult population with diabetic macular edema and age-related macular degeneration [38][39][40]. Since diabetic macular edema and ROP are results of retinal vascular disturbances, we can assume that IVB and IVR might cause reduction in choroidal thickness and volume in infants with ROP, which in turn might affect the choroidal mechanisms of emmetropization.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Bevacizumab and Ranibizumab in the Treatment of Type 1 Retinopathy of Prematurity Affecting Zone 1

Kimyon

Mete²

2018

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To investigate the effects of bevacizumab and ranibizumab in the treatment of type 1 retinopathy of prematurity (ROP) affecting zone 1. Methods: Files of the patients who received intravitreal bevacizumab (IVB) or ranibizumab (IVR) treatment for ROP affecting zone 1 were evaluated retrospectively. Spherical equivalent (SE) and axial length (AXL) measurements were performed at 1 year of adjusted age. Results: Sixty-eight eyes of 37 patients were included in the study. All patients had initial disease regression but 6 patients (4 in the IVB, 2 in the IVR group) showed reactivation (p = 0.679). The number of eyes with incomplete vascularization were 15 and 12 in the IVB and IVR groups, respectively (p = 0.725). Mean AXL was 20.50 ± 0.99 mm in the IVB group and 19.30 ± 0.48 mm in the IVR group (p < 0.001). Mean SE was –1.49 ± 2.38 dpt in the IVB group and 0.98 ± 2.18 dpt in the IVR group (p < 0.001). Conclusion: Bevacizumab and ranibizumab showed similar effectiveness in the treatment of type 1 ROP affecting zone 1. The AXL was longer and SE was more myopic in eyes treated with IVB. This difference might be caused by the longer intravitreal half-life of bevacizumab than ranibizumab.

show abstract

“…In previous studies, a decrease in CT was noted in the eyes that underwent anti-VEGF therapy, regardless of the type of anti-VEGF agents used. 9–12 This trend was also noted in eyes with Type 3 MNV, 9,11,13,14 which generally develops in eyes with a very thin choroid. 15,16 It is postulated that the thin choroid in eyes with Type 3 MNV may induce hypoxic conditions in the retina and thus contribute to the development of intraretinal MNV.…”

mentioning

confidence: 70%

“…Although a significant decrease in CT after anti-VEGF therapy has been reported, [9][10][11][12] there has been controversy as to whether this decrease is actually because of the effect of anti-VEGF. In some studies, a decrease in CT was not noted after anti-VEGF therapy.…”

Section: Discussionmentioning

confidence: 99%

Long-Term Changes in Choroidal Thickness in Eyes With Type 3 Macular Neovascularization

Kim

et al. 2021

Retina

View full text Add to dashboard Cite

Purpose: To evaluate the long-term changes in subfoveal choroidal thickness (SCT) in eyes with Type 3 macular neovascularization that underwent anti-vascular endothelial growth factor therapy.Methods: This retrospective study was performed with 47 patients diagnosed with Type 3 macular neovascularization and treated with anti-vascular endothelial growth factor therapy. All the patients initially received three loading injections. The SCT was compared at diagnosis, 3 months, 12 months, and at the final follow-up visit. The velocity of changes in SCT was also compared between each period.Results: The mean follow-up period was 52.1 ± 11.0 months. The mean SCT was 143.3 ± 51.2 mm at diagnosis, and it had significantly decreased to 128.6 ± 47.4 mm at 3 months (P , 0.001), 123.2 ± 45.7 mm at 12 months (P , 0.001), and 110.0 ± 43.0 mm at the final follow-up (P , 0.001). The mean velocity of the decrease in SCT was 4.9 ± 3.9 mm per month during the first 3 months, 0.6 ± 1.2 mm per month between the 3rd and the 12th months, and 0.3 ± 0.3 mm per month between the 12th month and the final follow-up. The velocity of the decrease was significantly greater during the first 3 months than during the 3rd to 12th month (P , 0.001) and 12th month to final follow-up (P , 0.001) periods. The difference was not significant between the 3rd to 12th month and 12th months to final follow-up (P = 0.836) periods.Conclusion: Subfoveal choroidal thickness continuously decreased over time, with a significant decrease of 23% noted in eyes with Type 3 macular neovascularization. The thickness rapidly decreased during the initial loading phase. Subsequently, a continuous but gradual decrease in the thickness was noted.

show abstract

Macular Choroidal Volume Changes After Intravitreal Bevacizumab for Exudative Age-Related Macular Degeneration

Abstract: The macular choroidal volume and the subfoveal choroidal thickness decreased significantly after 3 monthly bevacizumab injections for exudative age-related macular degeneration.

Cited by 3 publications

References 29 publications

Prospective Study of Vessel Density by Optical Coherence Tomography Angiography After Intravitreal Bevacizumab in Exudative Age-Related Macular Degeneration

Prospective Study of Vessel Density by Optical Coherence Tomography Angiography After Intravitreal Bevacizumab in Exudative Age-Related Macular Degeneration

Comparison of Bevacizumab and Ranibizumab in the Treatment of Type 1 Retinopathy of Prematurity Affecting Zone 1

Long-Term Changes in Choroidal Thickness in Eyes With Type 3 Macular Neovascularization

Contact Info

Product

Resources

About